News
Public · Published
Agenus Announces Nature Medicine Publication of Multicenter UNICORN Phase 2 Trial Demonstrating Deep Responses with Neoadjuvant BOT+BAL in Resectable Colon Cancer
Agenus announced that Nature Medicine published results from the investigator-sponsored Phase 2 UNICORN trial of preoperative botensilimab alone or with balstilimab in resectable, locally advanced colon cancer. The trial enrolled 56 patients; among 14 with pMMR/MSS disease given the combination, 36% had a major pathologic response and 29% had no viable tumor at surgery.
Published:
Updated:
What happened
Agenus announced that Nature Medicine published results from the investigator-sponsored Phase 2 UNICORN trial of preoperative botensilimab alone or with balstilimab in resectable, locally advanced colon cancer. The trial enrolled 56 patients; among 14 with pMMR/MSS disease given the combination, 36% had a major pathologic response and 29% had no viable tumor at surgery.
Confirmed
Global impact / market context
The reported tumor responses provide clinical evidence for Agenus’s drug combination in a defined colon cancer group, but the evidence comes from only 14 treated patients in a non-randomized study. Further results and testing would determine whether these findings translate into reliable patient benefit and commercial opportunity.
Analyst inference
Publication in a peer-reviewed journal makes the trial findings accessible, but does not establish that the treatment is approved or superior to other care. Because the study included four small, non-randomized groups, investors have limited grounds to judge broader effectiveness, safety, or future sales from this excerpt alone.
Analyst inference
What to watch
- Look for complete published results across all four cohorts, including response measures, event-free survival, safety, and follow-up, since the supplied article excerpt reports only one group’s response rates. Analyst inference
- Watch for any announced next clinical studies or regulatory steps; the article describes a Phase 2 trial and journal publication, not approval or a confirmed development timetable. Analyst inference
- A major pathologic response means 10% or less viable tumor remained at surgery; a pathologic complete response means no viable tumor remained, according to the article. Confirmed
Evidence
- Original source link unavailable